Adipokines and the Risk of Reflux Esophagitis

March 21, 2012 updated by: Donghee Kim, Seoul National University Hospital

Adipokines and the Risk of Reflux Esophagitis : Prospective Case-control Study

We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Kyung-Sang Yu, Professor
  • Phone Number: +82-2-2072-1920
  • Email: ksyu@snu.ac.kr

Study Contact Backup

  • Name: Jeong-Hwa Hong, IRB analyst
  • Phone Number: +82-2-740-8096
  • Email: jhhong@snu.ac.kr

Study Locations

  • Korea, Republic of
      • Seoul, Korea, Republic of
        • Seoul National University Hospital Healthcare System Gangnam Center
        • Contact:
        • Principal Investigator:
          • Donghee Kim, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

healthy adults who visit healthcare system for routine checkup

Description

Inclusion Criteria:

  • endoscopically proven reflux esophagitis

Exclusion Criteria:

  • those with esophageal hiatal hernia, current PPI medication, upper GI operation history

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Reflux esophagitis
those with endoscopically proven reflux esophagitis
Normal
those with normal GFS finding (without definite mucosal break at Z-line)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Difference in serum adipokine levels between case and control groups
Time Frame: 2 month lager (after sampling)
2 month lager (after sampling)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Anticipated)

June 1, 2013

Study Registration Dates

First Submitted

March 20, 2012

First Submitted That Met QC Criteria

March 21, 2012

First Posted (Estimate)

March 22, 2012

Study Record Updates

Last Update Posted (Estimate)

March 22, 2012

Last Update Submitted That Met QC Criteria

March 21, 2012

Last Verified

March 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • gerdadipokine

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Visceral Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe